Under Asc 605 was Voyager Therapeutics’s largest revenue line in fiscal 2018, bringing in $11.10M of $7.62M (146%).
| Initial Application Period Cumulative Effect Transition (2) | FY 2018 |
|---|---|
| Under Asc 605 | $11.10M |
| Effect Of Change | -$3.48M |
| Total | $7.62M |
Voyager Therapeutics brought in $7.62M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Under Asc 605 was the largest at $11.10M (145.6%).
The total is net of Effect Of Change, which took $3.48M off revenue in fiscal 2018.
Voyager Therapeutics (VYGR) reports its revenue by initial application period cumulative effect transition (2). In fiscal 2018, Under Asc 605 was its largest revenue line, bringing in $11.10M (145.6% of the total).
Under Asc 605 was Voyager Therapeutics' largest revenue line in fiscal 2018, bringing in $11.10M, or 145.6% of the $7.62M total across its two revenue lines.
Every figure comes from Voyager Therapeutics' annual financial filings, as reported. Each line keeps the name Voyager Therapeutics gives it, and years follow its fiscal calendar.
Voyager Therapeutics' revenue by initial application period cumulative effect transition (2) goes back to fiscal 2018, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.